Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report released on Tuesday,Benzinga reports. The firm currently has a $18.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.81) EPS, Q4 2025 earnings at ($2.00) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.50) EPS, FY2027 earnings at ($9.80) EPS, FY2028 earnings at ($9.50) EPS and FY2029 earnings at ($8.15) EPS.

Other equities analysts have also recently issued research reports about the stock. Robert W. Baird dropped their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Two equities research analysts have rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $7.50 on Tuesday. Enanta Pharmaceuticals has a one year low of $4.71 and a one year high of $17.80. The business has a 50 day simple moving average of $5.75 and a 200 day simple moving average of $9.51. The stock has a market capitalization of $159.98 million, a P/E ratio of -1.37 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. Equities analysts expect that Enanta Pharmaceuticals will post -5.05 earnings per share for the current year.

Insiders Place Their Bets

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 13.89% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE raised its position in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares during the period. Quest Partners LLC lifted its holdings in Enanta Pharmaceuticals by 65.0% during the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 7,535 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Enanta Pharmaceuticals during the 3rd quarter worth about $122,000. Valence8 US LP bought a new stake in Enanta Pharmaceuticals during the 3rd quarter worth approximately $207,000. Finally, FMR LLC boosted its stake in Enanta Pharmaceuticals by 18.9% during the third quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock valued at $511,000 after buying an additional 7,839 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.